A Holistic Phase Appropriate Strategy for HCP-Limits and HCP Characterization
Posted on September 21, 2026
Dr. Markus Haindl, Global Head Gene Therapy Technical Research & Development, Roche Diagnostics GmbH, Germany
Introduction During manufacturing of biopharmaceuticals prokaryotic and eukaryotic protein expression host systems like Escherichia coli (E. coli) and Chinese Hamster Ovary (CHO) cells generate a heterogeneous mixture of the desired therapeutic protein and a variety of endogenous host cell proteins ...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
